Roberto Burioni, non si può dire nulla di lui, perché tutti all’unisono sono d’accordo al governo. Per i nostri politici Burioni é l’unico super esperto di vaccini mentre il popolo bue non ha diritto di parola né di minima contestazione. Se poi chi contesta é un medico, allora occhio anche alla carriera perché c’è il pericolo radiazione. Lo avete visto come si é ridotto il primario mantovano De Donno che in preda ad un impeto di orgoglio aveva contestato il grande Burioni su Facebook? Gli hanno consigliato di abbandonare tutti i social con tanto di testo d’addio da leggere a tutti i suoi followers. La grancassa dei media al servizio del sistema corrotto di Big Pharma poi, é sempre pronta a diffondere pseudo verità scientifiche spacciate per Vangelo tanto gli italiani cretini, o comunque buona parte di loro, sono lì pronti a berle tutte d’un fiato.
Ma io come al solito ho il bruttissimo vizio di pormi delle domande e così mi sono chiesta:
Ma quali interessi ha Burioni nei confronti dei vaccini?
Perché tutta questa guerra tra medici, scienziati e virologi?
Davvero si battono per il nostro bene o solo per il loro interesse?
Uno come il grande Burioni, sua eccellenza Burioni, sua santità Burioni che cosa ci può guadagnare dai vaccini?
E così come al solito mi sono messa a fare qualche ricerchina e ho scoperto che Burioni ne ha veramente tanti di brevetti vaccinali o di sostanze utili alla formulazione degli stessi. Dunque é chiaro che uno come Burioni ha tutto l’interesse che i vengano resi obbligatori o quantomeno diffusi su larga scala, se poi é a livello mondiale tanto di guadagnato.
Burioni tra le altre cose è anche uno degli scienziati di punta della Pomona Ricerca srl, quindi andando a vedere di cosa si occupa la Pomona sul sito dell’azienda e sulla descrizione si legge: “il loro lavoro (cioè quello di Burioni e di un altro scienziato, Massimo Clementi) mette Pomona in una posizione leader per la progettazione e lo sviluppo di vaccini innovativi”, sempre nell’ambito degli anticorpi.
Ma chi é questo Clementi? Personalmente credo che proprio Clementi sia il classico topo da laboratorio che passa la vita tra microscopi, provette e campioni virali di ogni genere e specie. Credo che proprio Clementi sia il cervello dell’intera produzione, mentre Burioni sia più che altro l’immagine radical chic della solita becera propaganda vaccinale. Lui, per intenderci, é quello “FICO” che fa mille cose contemporaneamente. Lui é quello che in tempo di ricerca ed emergenza coronavirus trova il tempo di scrivere libri, lui é quello che salta come un grillo di trasmissione in trasmissione come fosse una star e rilascia interviste ma solo ai giornalisti che prima gli chiedono l’autografo. Burioni é il classico che fa tutto, fa tutto presto e bene e come al solito non pulisce il water perché poi le tracce si scoprono.
Su Clementi, tralasciando il chilometrico curriculum che si costruiscono un po’ tutti nell’ambiente, é una creatura di don Luigi Verzé, il grande amico di Silvio Berlusconi dove proprio grazie a Berlusconi ha avuto modo ci incontrare l’amico per la vita e collega, l’altissimo eccellentissimo venerabilissimo sua eccellenza Burioni. Perché come é facile capire, i politici degli ultimi decenni danno luogo al solito teatrino che li vede gli uni contro gli altri, ma alla fine sono tutti conniventi tra loro.
Mio padre per esempio, mi dice sempre: “buona parte di quelli che oggi sono in politica, é tutta gente che di giorno lavora a sinistra e poi, la sera, prega a destra”.
Tornando al tandem Burioni/Clementi però le connivenze a destra e sinistra sono di vero rilievo. Iniziamo per esempio a dire che nell’arco d’un decennio, cioè dal 2006 al 2016, depositano una vera e propria montagna di brevetti.
I committenti sono tutte aziende di un certo calibro:
vi é la già citata Pomona Ricerca srl, spicca il colosso Bracco Imaging spa, c’è la Ribovax Biotecnologie SA, la Generale Anticorpi e ultima, ma non per importanza Biotecnologie srl.
Ho scoperto inoltre, ma questa volta da un sito estero, che sempre Pomona é una compagnia privata che opera nel settore delle biotecnologie e impegnata nello studio, sviluppo e produzione di anticorpi umani monoclonali in grado di combattere varie patologie virali come l’epatite C, i virus influenzali come il CoronaVirus, l’JC virus. Fondata nel 2010, la società ha nel corso degli anni acquisito gli asset e la proprietà intellettuale di diverse piccole compagnie che si occupano di biotecnologie, il tutto basato sulle ricerche di due professori dell’Università San Raffaele.
Ecco che i professori Clementi e Burioni arrivano in breve tempo ad essere considerati tra i ‘key opinion leaders’ (gli esperti ‘chiave’) e gli esperti di maggior livello internazionale. La loro consolidata esperienza consente a Pomona di occupare una posizione leader nel settore. Pomona Ricerca è finanziata da “angel investors”, ossia da finanziatori con le ali, come appunto gli angeli.
Una di questi finanziatori con le ali é la Bracco, la meglio nota lady di ferro, Diana proprio colei che é stata anche un star dell’Expo di Milano, che qualche tempo fa insieme al Sindaco Sala ha avuto le sue gatte da pelare con la procura di Milano che per lei aveva chiesto 1 anno e tre mesi per la disinvolta gestione dei bilanci societari, con una serie di milioncini che erano sublimati e pare siano serviti per mantenere le ville a Capri o in Costa Azzurra. Bazzecole per una Paperona come lei, la stessa le ha considerate – “sviste amministrative”. La Bracco Imaging spa ha il suo quartier generale a Trieste e – come viene descritto nel sito – “è un’azienda leader globale nella diagnostica per immagini. Una multinazionale presente in oltre 90 paesi di tutto il mondo, direttamente o indirettamente attraverso società controllate o joint ventures, con una forte leadership nelle aree geografiche più significative. Le loro attività di ricerca sono situate in Italia, Stati Uniti e Svizzera.
E proprio a Ginevra, in Svizzera, si trova la sede principale di Ribovax Biotecnologies Sa, una società anonima localizzata in Avenue des Morgines, all’interno del mega Business Center della incantevole città elvetica.
Questa che vi ho narrato fino ad ora, era solo una breve introduzione ai brevetti dell’inventore Roberto Burioni.
Ora arriviamo alla ciccia come si suol dire.
Roberto Burioni ha depositato brevetti per proteggere le seguenti invenzioni per le quali detiene i diritti. L’elenco che segue include domande di brevetto in sospeso, così come i brevetti già concessi dagli Stati Uniti Patent and Trademark Office (USPTO) che allego.
Partiamo dall’invenzione che porta, come numero progressivo, il 20160200801, “data di archiviazione 29 marzo 2016, data di pubblicazione 14 luglio 2016, richiedente Pomona Ricerca srl”. Ecco il cosiddetto abstract: “Anticorpi monoclonali diretti contro il virus influenzale A” e alla fine dopo un’articolata descrizione: “Gli anticorpi monoclonali possono essere utilizzati anche per testare preparazioni di anticorpi da utilizzare come vaccini”.
Poi procedendo a ritroso troviamo il brevetto 20160060325, archiviato l’11 novembre 2015 e pubblicato il 3 marzo 2016. A richiederlo la solita Pomona. Si tratta di una variazione della precedente ricerca, e perciò riguarda sempre il virus influenzale A.
lo precede il 9200054, sempre con Pomona come assegnatario ma stavolta si evidenzia un forte sfalso nelle date: archiviato il 27 maggio 2009, la data finale è quella del 26 gennaio 2016. Sorge spontanea una domanda: come fa ad averlo richiesto, Pomona, se all’epoca ancora non esisteva dato che la stessa Pomona è nata nel 2010? Misteri delle bioscienze Burioniane. Il tema è sempre lo stesso, anche se con qualche piccola variazione: vaccini per il virus influenzale A, un vero pozzo di San Patrizio.
Ancora la solita storia della data si evince con il brevetto 9200063, ancora Pomona, date molto lontane, ossia archiviazione a marzo 2009 e brevetto rilasciato il 1 dicembre 2015. Resta quell’interrogativo su come Pomona abbia potuto presentarlo se nemmeno esisteva ancora.
Arriviamo al brevetto 8486406 Pomona, archiviato il 1 giugno 2010 (e qui con le date ci possiamo stare) e varato a luglio 2013, stavolta riguardante un altro tema: “l’uso di anticorpi monoclonali FAB28 e FAB49 per il trattamento profilattico e terapeutico di influenza A di origine suina”. Ne trovò un altro e cioè il brevetto 8623363, c’è una strana incongruenza sulle date anche qui, dall’archiviazione del 21 dicembre 2009 (le date non si trovano) e la ratifica del brevetto del 7 gennaio 2014. Ricambia il tema: “La presente invenzione riguarda l’anticorpo monoclonale E20 o un frammento funzionale di esso come un medicamento per il trattamento terapeutico e prevenzione delle infezioni da HCV”.
Ancor più strane le date in occasione del brevetto 8367061. Pomona non manca mai all’appello, ma l’archiviazione è nientemeno che di inizio 2008 (per la precisione del 29 gennaio 2008) quando Pomona era ancora ben lontana dall’essere pensata e concepita, e il brevetto reca la data di febbraio 2013. Poco chiaro l’abstract: “Novel anti-idiotipo sono descritti anticorpi monoclonali che sono in grado di specificamente reagire con l’idiotipo di anticorpi anti-gp120 umani, di inibire il legame tra antigene gp120 e anticorpi anti-gp120 umani” e via farneticando.
Rientriamo fra i ranghi con il brevetto 20130022608, archiviato a marzo 2011 e pubblicato meno di due anni dopo, gennaio 2013. Tema di nuovo a base di virus influenzale A e in particolare “gli anticorpi monoclonali che sono immunoglobuline lg-G isotopo full-lenght e che sono caratterizzati da una elevata attività neutralizzante ad ampio raggio contro il virus influenzale A”.
Passiamo ai brevetti richiesti a Burioni e Clementi dalla paperona Diana di Bracco Imaging spa. Eccoci al numero 20120165211: stavolta non passano anni, il potere economico della Bracco evidentemente unge e ingrassa gli ingranaggi giusti e così, dall’archiviazione alla pubblicazione passano solo pochissimi mesi: 13 gennaio 2012 l’archiviazione e 28 giugno 2012 la pubblicazione. Rapidi come saette grazie alla signora di ferro, le cose filano che é un piacere. Stavolta, però gli inventori sono 4: accanto ai due, infatti, ritroviamo anche Filippo Canducci e Federico Maisano. Denso l’abstract: “La presente invenzione si riferisce ad anticorpi umane derivate da librerie anticorpali umani preparati dalle placche aterosclerotiche”. Segue una arci arzigogolata descrizione scientifica.
Due anni passano per un altro brevetto, il 20120115741, per la precisione dal 17 marzo 2010 al 10 maggio 2012: “la presente invenzione descrive anticorpi o frammenti di esso in grado di legarsi isolate campioni di placca coronarica e dei processi per la loro produzione utilizzando le cellule ospiti contenenti sequenze di DNA che codificano per gli anticorpi detto di frammenti della stessa”. Poco chiaro a mortali e non, ma andiamo avanti.
Sempre poco più di due anni (settembre 2008-dicembre 2010) per il brevetto 20100316563: “un processo è previsto per la preparazione di anticorpi o loro frammenti utilizzando una cellula ospite procariota contenente sequenze di DNA che codificano per detti anticorpi di loro frammenti, in cui detta sequenza di DNA è derivata da un campione di placca coronarica”.
Un virus? Si, c’è anche quello!Eccoci alla ginevrina Ribovax Biotecnologie Sa. Si tratta delle invenzioni più antiche, praticamente anche oltre una decina d’anni fa.
Partiamo dal brevetto 7811973, archiviazione a luglio 2006, pubblicazione quattro anni più tardi, ottobre 2010: “La presente invenzione fornisce nuove tecnologie per la produzione e screening proteine di fusione sulla superficie del fago filamentoso”.
Marzo 2008, giugno 2010 per il brevetto 20100143376: “la presente invenzione fornisce sequenze di anticorpi romanzo che si legano e neutralizzano Rosolia Virus (RUV)”.
Pressochè identico arco temporale (febbraio 2008-marzo 2010) per il numero 20100074906, “la presente invenzione fornisce sequenze di anticorpi che si legano nuovi Varicella Zoster (VZV) e neutralizzare l’infezione VZV”…
Per finire con la Generale Anticorpi e Biotecnologie srl, alla quale il magico tandem d’attacco (ai vaccini) recapita un solo brevetto, il numero 7727529, archiviato a maggio 2008 e ratificato due anni dopo, giugno 2010. “L’invenzione si riferisce ad un anticorpo umano o ai suoi frammenti funzionali, diretto contro la glicopropteina E2 di HCV, in grado di avere una attività neutralizzante in vivo; una composizione per la terapia anti-HCV comprendente una quantità terapeuticamente efficace dell’anticorpo; una composizione per uso topico in gel, creme, pomate e formulazione ovuli; l’uso di anticorpi per la convalida vaccini anti HCV”.
Fermi lì che siamo solo a metà strada. Ed ecco ora tutti i brevetti registrati in America.
Patents by Inventor Roberto Burioni
Roberto Burioni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
Human monoclonal antibodies endowed with strong neutralizing activity against HSV-1 and HSV-2
Patent number: 10626167
Abstract: The present invention is in the field of monoclonal antibodies suitable for passive immunotherapy of Herpes Simplex Virus infections and relates to human monoclonal antibodies or fragments of said antibodies, which bind and neutralize HSV-1 and HSV-2, and their use in the prophylaxis or treatment of HSV-1 or HSV-2-associated diseases.
Type: Grant Filed: January 28, 2016 Date of Patent: April 21, 2020 Assignee: POLICHEM S.A. Inventors: Roberto Burioni, Massimo Clementi, Daniela Concas
ANTI-HSV SYNERGISTIC ACTIVITY OF ANTIBODIES AND ANTIVIRAL AGENTS
Publication number: 20190185546 Abstract: The present invention relates to a combination comprising HSV-1 and HSV-2 binding monoclonal antibodies or fragments thereof and antiviral agents, the pharmaceutical formulations comprising said combination, optionally together with an excipient pharmaceutically acceptable and its use in the prophylaxis and/or treatment of herpes virus infections, including genital herpes, HSV gingivostomatitis and recurrent herpes labialis, herpes simplex encephalitis (HSE), neonatal HSV, HSV disease in the immunocompromised host and HSV keratitis keratoconjunctivitis. Type: Application Filed: July 26, 2017 Publication date: June 20, 2019 Applicant: Polichem S.A. Inventors: Roberto Burioni, Massimo Clementi
Human monoclonal antibody against the VP1 protein of JC virus
Patent number: 10011648
Abstract: A human neutralizing monoclonal antibody is directed against the VP1 protein of JC virus. The JC virus is responsible for progressive multifocal leukoencephalopathy (PML). The antibody is used in a therapeutic or prophylactic treatment of a JCV infection or of a disease associated with a JCV infection, such as progressive multifocal leukoencephalopathy (PML). The antibody is also used in the diagnosis of JCV infections or of diseases associated with JCV infections. Type: Grant Filed: June 26, 2013 Date of Patent: July 3, 2018 Assignee: POMONA RICERCA S.r.l. Inventors: Roberto Burioni, Massimo Clementi
HUMAN MONOCLONAL ANTIBODIES ENDOWED WITH STRONG NEUTRALIZING ACTIVITY AGAINST HSV-1 AND HSV-2
Publication number: 20180009879 Abstract: The present invention is in the field of monoclonal antibodies suitable for passive immunotherapy of Herpes Simplex Virus infections and relates to human monoclonal antibodies or fragments of said antibodies, which bind and neutralize HSV-1 and HSV-2, and their use in the prophylaxis or treatment of HSV-1 or HSV-2-associated diseases. Type: Application Filed: January 28, 2016 Publication date: January 11, 2018 Inventors: Roberto BURIONI, Massimo CLEMENTI, Daniela CONCAS
Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes
Patent number: 9598482
Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies described herein, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies described herein. The monoclonal antibodies can also be used for testing antibody preparations to be used as vaccines. Type: Grant Filed: March 29, 2016 Date of Patent: March 21, 2017 Assignee: Pomona Ricerca S.r.l. Inventors: Roberto Burioni, Massimo Clementi
Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes
Patent number: 9587011 Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines. Type: Grant Filed: November 11, 2015 Date of Patent: March 7, 2017 Assignee: Pomona Ricerca S.r.l. Inventors: Roberto Burioni, Massimo Clementi
Monoclonal Antibodies Capable of Reacting with a Plurality of Influenza Virus A Subtypes
Publication number: 20160200801 Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies described herein, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies described herein. The monoclonal antibodies can also be used for testing antibody preparations to be used as vaccines. Type: Application Filed: March 29, 2016 Publication date: July 14, 2016 Applicant: Pomona Ricerca S.r.l. Inventors: Roberto Burioni, Massimo Clementi
Monoclonal Antibodies Capable of Reacting with a Plurality of Influenza Virus a Subtypes
Publication number: 20160060325 Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines. Type: Application Filed: November 11, 2015 Publication date: March 3, 2016 Applicant: POMONA RICERCA S.R.L. Inventors: Roberto Burioni, Massimo Clementi
Monoclonal antibodies having homosubtype cross-neutralization properties against influenza A viruses subtype H1
Patent number: 9243054
Abstract: A monoclonal antibody directed against the influenza A virus is described, which is capable of binding human and animal isolates of influenza A viruses expressing the H1-subtype hemagglutinin. A preferred embodiment is the antibody designated as Fab49, which shows a neutralizing activity against a plurality of influenza A virus isolates expressing the H1-subtype hemagglutinin, including animal-derived isolates. Anti-idiotype antibodies directed against the monoclonal antibody of the invention, immunogenic or vaccine compositions comprising the monoclonal antibody of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibody of the invention. The monoclonal antibody of the invention can also be employed for testing antibody preparations to be used as vaccines. Type: Grant Filed: May 27, 2009 Date of Patent: January 26, 2016 Assignee: POMONA RICERCA S.R.L. Inventors: Roberto Burioni, Massimo Clementi
Monoclonal antibodies capable of reacting with a plurality of influenza virus A subtypes
Patent number: 9200063
Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines. Type: Grant Filed: March 16, 2009 Date of Patent: December 1, 2015 Assignee: POMONA RICERCA S.R.L. Inventors: Roberto Burioni, Massimo Clementi
HUMAN MONOCLONAL ANTIBODY AGAINST THE VP1 PROTEIN OF JC VIRUS
Publication number: 20150191530 Abstract: A human neutralizing monoclonal antibody is directed against the VP1 protein of JC virus. The JC virus is responsible for progressive multifocal leukoencephalopathy (PML). The antibody is used in a therapeutic or prophylactic treatment of a JCV infection or of a disease associated with a JCV infection, such as progressive multifocal leukoencephalopathy (PML). The antibody is also used in the diagnosis of JCV infections or of diseases associated with JCV infections. Type: Application Filed: June 26, 2013 Publication date: July 9, 2015 Inventors: Roberto Burioni, Massimo Clementi
Anti-HCV monoclonal antibody as a medicament for the therapeutic treatment and prevention of HCV infections
Patent number: 8623363
Abstract: The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes 1a, 1b, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents.
Type: Grant Filed: December 21, 2009 Date of Patent: January 7, 2014 Assignee: Pomona Ricerca S.R.L. Inventors: Roberto Burioni, Massimo Clementi
Monoclonal antibodies as a medicament for the therapeutic and/or prophylactic treatment of swine-origin influenza A (H1N1) virus (S-OIV) infections
Patent number: 8486406
Abstract: The use of monoclonal antibodies Fab28 and Fab49 for the prophylactic or therapeutic treatment of swine-origin influenza A (H1N1) virus (S-OIV) infections is described, the which virus is responsible for the influenza syndrome commonly known as “swine flu”. Moreover, the use of the above-mentioned antibodies for selecting potential vaccines for active immunization against S-OIV is described.
Type: Grant Filed: June 1, 2010
Date of Patent: July 16, 2013 Assignee: Pomona Ricerca S.R.L.
Inventors: Roberto Burioni, Massimo Clementi
Anti-idiotype monoclonal antibodies mimicking the HIV gp120 CD4-binding (CD4bs)
Patent number: 8367061
Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.
Type: Grant Filed: January 29, 2008 Date of Patent: February 5, 2013 Assignee: Pomona Ricera S.R.L. Inventors: Roberto Burioni, Massimo Clementi
FULL-LENGTH IgG IMMUNOGLOBULINS CAPABLE OF RECOGNIZING A HETEROSUBTYPE NEUTRALIZING EPITOPE ON THE HEMAGGLUTININ STEM REGION AND USES THEREOF
Publication number: 20130022608 Abstract: Monoclonal antibodies that are full-length IgG-isotype immunoglobulins and that are characterized by a high broad-range neutralizing activity against the influenza A virus and capable of recognizing a specific hemagglutinin epitope that is highly conserved among different influenza A virus subtypes are provided. Also provided are therapeutic, prophylactic and diagnostic uses of such immunoglobulins.
Type: Application Filed: March 25, 2011 Publication date: January 24, 2013 Applicant: Pomona Ricerca S.r.l. Inventors: Roberto Burioni, Massimo Clementi
MONOCLONAL ANTIBODIES AS A MEDICAMENT FOR THE THERAPEUTIC AND/OR PROPHYLACTIC TREATMENT OF SWINE-ORIGIN INFLUENZA A (H1N1) VIRUS (S-OIV) INFECTIONS
Publication number: 20120225068 Abstract: The use of monoclonal antibodies Fab28 and Fab49 for the prophylactic or therapeutic treatment of swine-origin influenza A (H1N1) virus (S-OIV) infections is described, the which virus is responsible for the influenza syndrome commonly known as “swine flu”. Moreover, the use of the above-mentioned antibodies for selecting potential vaccines for active immunization against S-OIV is described.
Type: Application Filed: June 1, 2010 Publication date: September 6, 2012 Inventors: Roberto Burioni, Massimo Clementi
Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques
Publication number: 20120165211 Abstract: The present invention refers to human antibodies derived from human antibody libraries prepared from atherosclerotic plaques. It further refers to human antibodies able to immunologically recognize both human transgelin or fragments thereof and a protein with at least 50% similarity to OmpK36 (Outer membrane protein, Klebsiella, K36; GI: 295881594) or fragments thereof. Human transgelin is preferably transgelin 1 (Accession N° Q01995, GI:48255907). The antibodies further recognize an antigen in the atherosclerotic plaque and are useful for the preparation of immunodiagnostic reagents or assays to detect atherogenic diseases. The invention also relates to the use of anti-TAGLN monoclonal antibodies, showing cross-reactivity with a bacterial antigen having at least 50% similarity with OmpK36, for detecting antigens in the atherosclerotic plaque or as atherosclerotic related reagents in an immuno-competition assay.
Type: Application Filed: January 13, 2012 Publication date: June 28, 2012 Applicant: BRACCO IMAGING S.P.A. Inventors: Roberto BURIONI, Filippo CANDUCCI, Massimo CLEMENTI, Federico MAISANO
Reagents For The Atherosclerotic Coronary Plaque And Uses Thereof
Publication number: 20120115741 Abstract: The present invention discloses antibodies or fragments thereof able to bind isolated coronary plaque samples and processes for their production using host cells containing DNA sequences encoding for said antibodies of fragments thereof. Methods for screening ligands to said isolated samples are also described, and compositions containing said antibodies are also provided.
Type: Application Filed: March 17, 2010 Publication date: May 10, 2012 Applicant: BRACCO IMAGING S.P.A. Inventors: Massimo Clementi, Roberto Burioni
ANTI-HCV MONOCLONAL ANTIBODY AS A MEDICAMENT FOR THE THERAPUTIC TREATMENT AND PREVENTION OF HCV INFECTIONS
Publication number: 20110256140 Abstract: The present invention relates to the monoclonal antibody e20 or a functional fragment thereof as a medicament for the therapeutic treatment and prevention of HCV infections. The e20 antibody is able to bind all of the known HCV genotypes and exhibits a strong neutralising activity against the virus, in particular towards genotypes 1a, 1b, 2a, and 4. A pharmaceutical composition is also described for the treatment or prevention of HCV infections, which comprises the monoclonal antibody e20 or a functional fragment thereof, and pharmaceutically acceptable excipients, carriers or diluents.
Type: Application Filed: December 21, 2009 Publication date: October 20, 2011 Inventors: Roberto Burioni, Massimo Clememti
MONOCLONAL ANTIBODIES HAVING HOMOSUBTYPE CROSS-NEUTRALIZATION PROPERTIES AGAINST INFLUENZA A VIRUSES SUBTYPE H1
Publication number: 20110076265 Abstract: A monoclonal antibody directed against the influenza A virus is described, which is capable of binding human and animal isolates of influenza A viruses expressing the H1-subtype hemagglutinin. A preferred embodiment is the antibody designated as Fab49, which shows a neutralizing activity against a plurality of influenza A virus isolates expressing the H1-subtype hemagglutinin, including animal-derived isolates. Anti-idiotype antibodies directed against the monoclonal antibody of the invention, immunogenic or vaccine compositions comprising the monoclonal antibody of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibody of the invention. The monoclonal antibody of the invention can also be employed for testing antibody preparations to be used as vaccines.
Type: Application Filed: May 27, 2009 Publication date: March 31, 2011 Inventors: Roberto Burioni, Massimo Clementi
MONOCLONAL ANTIBODIES CAPABLE OF REACTING WITH A PLURALITY OF INFLUENZA VIRUS A SUBTYPES
Publication number: 20110014187 Abstract: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza A virus. Anti-idiotype antibodies directed against the monoclonal antibodies of the invention, immunogenic or vaccine compositions comprising the monoclonal antibodies of the invention are also described, as well as therapeutic, prophylactic and diagnostic applications for the monoclonal antibodies of the invention. The monoclonal antibodies of the invention can also be used for testing antibody preparations to be used as vaccines.
Type: Application Filed: March 16, 2009 Publication date: January 20, 2011 Inventors: Roberto Burioni, Massimo Clementi
Method For The Preparation Of New Oligoclonal Antibodies
Publication number: 20100316563 Abstract: A process is provided for the preparation of antibodies or fragments thereof using a prokaryotic host cell containing DNA sequences encoding for said antibodies of fragments thereof, wherein said DNA sequence is derived from a coronary plaque sample. Compositions containing said antibodies are also provided. Ligands to said antibodies and compositions containing said ligands are also described.
Type: Application Filed: September 18, 2008 Publication date: December 16, 2010 Applicant: BRACCO IMAGING S.P.A. Inventors: Massimo Clementi, Roberto Burioni
Phage display technologies
Patent number: 7811973
Abstract: The present invention provides novel technologies for producing and screening fusion proteins on the surface of filamentous phage. In particular, a single vector can be used for generating cell and phage libraries containing a given series of protein sequences fused to either one or other of two phage coat proteins. This approach simplifies and improves the efficiency of the subsequent phage display-based selection of protein-binding molecules having therapeutic or diagnostic utility, such as antibodies, peptides, or epitope-binding regions.
Type: Grant Filed: July 6, 2006 Date of Patent: October 12, 2010
Assignee: Ribovax Biotechnologies SA Inventors: Roberto Burioni, Massimo Clementi
Antibodies Specific for Rubella Virus
Publication number: 20100143376 Abstract: The present invention provides novel antibody sequences that bind and neutralize Rubella Virus (RuV). The novel sequences can be used for the medical management of RuV infection, in particular for detecting the virus or for preparing pharmaceutical compositions. The RuV-specific antigens recognized by such antibody sequences can be identified using novel phage libraries that display peptides. Type: Application Filed: March 6, 2008 Publication date: June 10, 2010 Applicant: RIBOVAX BIOTECHNOLOGIES S.A. Inventors: Roberto Burioni, Massimo Clementi
Human monoclonal antibody Fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity
Patent number: 7727529
Abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines. Type: Grant Filed: May 28, 2008 Date of Patent: June 1, 2010 Assignee: General Antibodies and Biotechnologies S.R.L Inventor: Roberto Burioni
Antibodies Specific for Varicella Zoster Virus
Publication number: 20100074906 Abstract: The present invention provides novel antibody sequences that bind Varicella Zoster Virus (VZV) and neutralize VZV infection. The novel sequences can be used for the medical management of VZV infection, in particular for detecting the virus or for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of VZV infection. Type: Application Filed: February 6, 2008 Publication date: March 25, 2010 Applicant: RIBOVAX BIOTECHNOLOGIES SA Inventors: Roberto Burioni, Massimo Clementi
ANTI-IDIOTYPE MONOCLONAL ANTIBODIES AS MIMOTOPES OF THE HIV GP120 ANTIGEN Publication number: 20100008905 Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed. Type: Application Filed: January 29, 2008 Publication date: January 14, 2010 Inventors: Roberto Burioni, Massimo Clementi
Complex able to detect an analyte, method for its preparation and uses thereof
Publication number: 20090203548 Abstract: A complex able to detect an analyte (CRA) comprising a particle expressing on its outer surface a compound having specific binding capability (CDCLS) for the analyte and stably including at least one nucleic acid reporter sequence being univocally associated to the CDCLS; process for its construction and uses thereof. Type: Application Filed: August 9, 2005 Publication date: August 13, 2009 Inventor: Roberto Burioni
Novel Phage Display Technologies
Publication number: 20080312101 Abstract: The present invention provides novel technologies for producing and screening fusion proteins on the surface of filamentous phage. In particular, a single vector can be used for generating cell and phage libraries containing a given series of protein sequences fused to either one or other of two phage coat proteins. This approach simplifies and improves the efficiency of the subsequent phage display-based selection of protein-binding molecules having therapeutic or diagnostic utility, such as antibodies, peptides, or epitope-binding regions. Type: Application Filed: July 6, 2006 Publication date: December 18, 2008 Inventors: Roberto Burioni, Massimo Clementi
HUMAN MONOCLONAL ANTIBODY FAB FRAGMENTS DIRECTED AGAINST HCV E2 GLYCOPROTEIN AND ENDOWED WITH IN VITRO NEUTRALIZING ACTIVITY
Publication number: 20080241162 Abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines. Type: Application Filed: May 28, 2008 Publication date: October 2, 2008 Inventor: ROBERTO BURIONI
Human recombinant antibody against the hepatitis C (HCV) non structural NS3 protein nucleic acid and uses thereof
Patent number: 7314919
Abstract: An human antibody anti-NS3 protein of the hepatitis C virus (HCV) is described, as will as synthetic and recombinant fragments thereof able to inhibit the helicase activity of the NS3 protein, both in vitro and in vivo, and uses thereof. Type: Grant Filed: June 11, 2002 Date of Patent: January 1, 2008 Assignee: Biostrands S.r.l. Inventors: Roberto Burioni, Massimo Clementi
Antibody for ligand capture assay
Patent number: 7060799
Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay. Type: Grant Filed: February 19, 2002 Date of Patent: June 13, 2006 Assignee: The Scripps Research Institute Inventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
Method for identifying the proteome of cells using an antibody library microarray
Publication number: 20050130320 Abstract: The invention describes a method for identifying the level of various proteins in a cells or tissue and also comparing the levels of the same protein in two different tissues which we have termed as Antibody Microarray Proteomics Technology (AMP Technology). Proteins that are differentially expressed between a normal and disease tissue could be involved in the disease process and disease tissue could be involved in the disease process and hereby makes it a potential drug or diagnostic target. AMP technology makes use of the method of phage display selection or similar combinatorial antibody selection techniques to select antibodies to a given protein. Antibodies to all of most proteins present in the diseased and normal tissue are produced in an appropriate animal (mice) and mRNA encoding antibodies are isolated, cloned into filamentous phage (or bacteria or yeast) vectors such that the antibodies are expressed as a fusion with the phage filaments. Type: Application Filed: November 8, 2001 Publication date: June 16, 2005 Inventors: Shaji. George, Roberto Burioni
Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
Publication number: 20050084845 abstract: The invention refers to a human antibody, or its functional fragments, directed against the HCV E2 glycoprotein, able to have a neutralizing activity in vivo; a composition for anti-HCV therapy comprising in a therapeutically effective amount the antibody; a composition for topical use in gel, creme, ointment and ovule formulations; the use of the antibody for validating anti-HCV vaccines. Type: Application Filed: January 29, 2003 Publication date: April 21, 2005 Inventor: Roberto Burioni
Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein nucleic acid and uses thereof
Publication number: 20040214994 Abstract: An human antibody anti-NS3 protein of the hepatitis C virus (HCV) is described, as will as synthetic and recombinant fragments thereof able to inhibit the helicase activity of the NS3 protein, both in vitro and in vivo, and uses thereof. Type: Application Filed: February 23, 2004 Publication date: October 28, 2004 Inventors: Roberto Burioni, Massimo Clementi
Ligand capture-directed selection of antibody
Publication number: 20020168629 Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay. Type: Application Filed: February 19, 2002 Publication date: November 14, 2002 Applicant: The Scripps Research Institute, a California Corporation Inventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
Ligand capture-directed selection of antibody
Patent number: 6376170
Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay. Type: Grant Filed: November 18, 1997 Date of Patent: April 23, 2002 Assignee: The Scripps Research Institute Inventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
Human monoclonal antibodies to herpes simplex virus and methods therefor
Patent number: 6156313
Abstract: The present invention describes human monoclonal antibodies which immunoreact with Herpes simplex virus Type-1 and Type-2. Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as nucleic acids and cell lines for producing the monoclonal antibodies. Type: Grant Filed: May 6, 1997 Date of Patent: December 5, 2000 Assignee: The Scripps Research Institute Inventors: Dennis R. Burton, Robert A. Williamson, Roberto Burioni, Pietro Paolo Sanna
Basta, finito, però se salta fuori ancora qualcosa ve lo posto. 😊
Come dice sua eccellenza l’altissimo Burioni: “i vaccini non sono un’opinione”!
EBurioniniCarissimo Burioni, vero, non saranno un’opinione, ma sopra ai vaccini e grazie a vari appoggi e ganci ci hai fatto un gran bel business.
Ciao ciao Dott. Burioni.
Un caro saluto dalla tua affezionata rompiscatole.. 😘😘😘
Italia Moli
Bravoio#IoSonoItalia🇮🇹
Io sono italia 